Evidence map›Paper›PMID 39820751›Full record

ArticleNature methods2025

Challenging the Astral mass analyzer to quantify up to 5,300 proteins per single cell at unseen accuracy to uncover cellular heterogeneity.

Julia A Bubis, Tabiwang N Arrey, Eugen Damoc, Bernard Delanghe, Jana Slovakova, Theresa M Sommer, Harunobu Kagawa, Peter Pichler, Nicolas Rivron, Karl Mechtler and 1 more

Abstract read
In one paragraph

Article in Nature methods, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed.

  1. Targeting T follicular helper cells for lifelong health.Nature reviews. Drug discovery · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Single-Injection Multi-Omics Analysis by Direct Infusion Mass Spectrometry.Angewandte Chemie (International ed. in English) · 2026
    Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Julia A Bubis *Research Institute of Molecular Pathology (IMP), Vienna BioCenter, Vienna, Austria. julia.bubis@imp.ac.at.ORCID http://orcid.org/0000-0002-4895-6146
Tabiwang N ArreyThermo Fisher Scientific, Bremen, Germany.
Eugen DamocThermo Fisher Scientific, Bremen, Germany.
Bernard DelangheThermo Fisher Scientific, Bremen, Germany.
Jana SlovakovaInstitute of Molecular Biotechnology (IMBA), Austrian Academy of Sciences, Vienna BioCenter, Vienna, Austria.
Theresa M SommerInstitute of Molecular Biotechnology (IMBA), Austrian Academy of Sciences, Vienna BioCenter, Vienna, Austria.
Harunobu KagawaInstitute of Molecular Biotechnology (IMBA), Austrian Academy of Sciences, Vienna BioCenter, Vienna, Austria.ORCID http://orcid.org/0000-0003-0436-3805
Peter PichlerResearch Institute of Molecular Pathology (IMP), Vienna BioCenter, Vienna, Austria.
Nicolas RivronInstitute of Molecular Biotechnology (IMBA), Austrian Academy of Sciences, Vienna BioCenter, Vienna, Austria.ORCID http://orcid.org/0000-0003-1590-5964
Karl MechtlerResearch Institute of Molecular Pathology (IMP), Vienna BioCenter, Vienna, Austria. karl.mechtler@imp.ac.at.ORCID http://orcid.org/0000-0002-3392-9946
Manuel Matzinger *Research Institute of Molecular Pathology (IMP), Vienna BioCenter, Vienna, Austria. manuel.matzinger@imp.ac.at.ORCID http://orcid.org/0000-0002-9765-7951

Funding

Austrian Science Fund (Fonds zur Förderung der Wissenschaftlichen Forschung) ESP497Austrian Science Fund (Fonds zur Förderung der Wissenschaftlichen Forschung) F 8801-BAustrian Science Fund (Fonds zur Förderung der Wissenschaftlichen Forschung) P35045-BÖsterreichische Forschungsförderungsgesellschaft (Austrian Research Promotion Agency) 2022/01 AT-SCPVienna Science and Technology Fund (Wiener Wissenschafts-, Forschungs- und Technologiefonds) LS20-079
6 · The paper itself

Abstract

Despite significant advancements in sample preparation, instrumentation and data analysis, single-cell proteomics is currently limited by proteomic depth and quantitative performance. Here we demonstrate highly improved depth of proteome coverage as well as accuracy and precision for quantification of ultra-low input amounts. Using a tailored library, we identify up to 7,400 protein groups from as little as 250 pg of HeLa cell peptides at a throughput of 50 samples per day. Using a two-proteome mix, we check for optimal parameters of quantification and show that fold change differences of 2 can still be successfully determined at single-cell-level inputs. Eventually, we apply our workflow to A549 cells, yielding a proteome coverage ranging from 1,801 to a maximum of >5,300 protein groups from a single cell depending on cell size and search strategy used, which allows for the study of dependencies between cell size and cell cycle phase. Additionally, our workflow enables us to distinguish between in vitro analogs of two human blastocyst lineages: naive human pluripotent stem cells (epiblast) and trophectoderm-like cells. Our data harmoniously align with transcriptomic data, indicating that single-cell proteomics possesses the capability to identify biologically relevant differences within the blastocyst.

Indexed as

Mass SpectrometryProteomeProteomicsSingle-Cell AnalysisA549 CellsHeLa CellsHumansProteome

Identifiers

PMID39820751
PMCPMC11903296

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.